Meeting
2019 ASCO Annual Meeting
Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.
Authors
Amit Hemadri
UPMC Cancer Center - UPMC Passavant, Pittsburgh, PA
Amit Hemadri , Huang Lin , Yan Lin , Amy Rose , Cindy Sander , Yana Najjar , Hassane M. Zarour , John M. Kirkwood , Diwakar Davar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9572)
DOI
10.1200/JCO.2019.37.15_suppl.9572
Abstract #
9572
Poster Bd #
143
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.
First Author: Amit Hemadri
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.
First Author: Kehe Chen
Poster
2020 Gastrointestinal Cancers Symposium
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
First Author: Hongjae Chon
Poster
2019 ASCO Annual Meeting
A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
First Author: Vaibhav Sahai